The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...

What This Means For You The FDA has expanded its approval of Kisquali, a drug already approved to treat advanced breast cancer, to include women with early disease.

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.